Trial Profile
Pilot Study of Sequential Angiogenic Blockade for the Treatment of Recurrent Mullerian Malignancies.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Cyclophosphamide (Primary)
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- 13 Apr 2016 Treatment arms changed from 2 to 1, trial focus changed from AR to TU.
- 13 Apr 2016 Status changed from active, no longer recruiting to completed.
- 07 Jun 2013 Planned End Date changed from 1 Feb 2013 to 1 Sep 2013 as reported by ClinicalTrials.gov.